 Okay guys we got Fabio on the line. Hey how's it going? Hey Fabio how you doing? It's Rich. Pleasure to meet you Fabio. We are live right now on YouTube. Okay awesome. Hi everyone. Yeah. Yeah so uh super excited to speak to you today and the stock is doing well. Congratulations stock's having a nice day. Oh thank you. Thank you very much. That's 44 cents in Canada right now. Up 12% and I believe it's at 33 cents up 10% in America. So Ph. R. M. Symbol Guys in Canada. Ph. R. R. F. is the symbol in America for anybody who's watching. Fabio I have a couple questions for you. Are you ready? Sure. Yeah absolutely. Awesome. So Fabio first and foremost can you tell us about Pharma Third Inc. and how it has evolved from when you founded the company? Yeah absolutely. So first of all I'm going to thank you for having this interview and to your audience. Thank you for joining and listening and about Pharma Third Inc. and its exciting developments in the psychedelics pharmaceutical space. So I'll just go a little bit about the background of the company. I founded Pharma Third Inc. and Pharma Third Inc. is focused on the next generation transdermal delivery of psychedelics pharmaceuticals with a specific focus on ketamine to treat mental health, neurological and pain disorders. Our patent portfolio consists of 19 patents and patent applications that cover the uses of ketamine, psilocybin and then the unique formulations of ketamine that is ready for a clinical trial and as well as a proprietary micro needle delivery patch or technology to deliver these psychedelic pharmaceuticals. So for instance our micro needle patch which would be applied to say your arm for a safe and effective delivery of these psychedelics and the problem in today which we're trying to solve is that all psychedelic therapies comes in several delivery forms such as nasal spray, intravenous injection or even oral ingestion such as psilocybin the actual mushroom as an edible. Now as in the case of psilocybin or ketamine a patient would need to be treated say in a hospital or clinic under supervision of say one or two healthcare providers for several hours and even up to even eight hours per session to monitor any side effects of these drugs would have such as hallucination, nausea, amnesia and whatnot just to make sure that they're okay. Our approach is deliver these psychedelic pharmaceuticals such as ketamine in a micro needle patch and actually a prototype you can even view it on our website or on our investor deck or corporate deck that is formulating a way to significantly reduce the side effects what we call the psychomimetic effects of these drugs such as hallucination, amnesia and nausea that's allowing the patient to treat their say their mental health such as depression safely and conveniently at home at their leisure with the way of having it being effective. Wow that's great sounds like yeah so really yeah absolutely like in essence our goal is to change the way psychedelics are used to treat these unmet medical needs with our particular focus which are lead programs in Parkinson's disease and depression. Wow now you mentioned it a little bit what are your main focuses on Pharmacere Inc for the first half of 2021 and some of the milestones the company has set to achieve? Yeah seeing that we're a focused psychedelic biotech company we are aiming to initiate two FDA phase two human clinical trials with ketamine in the treatment of Parkinson's disease as well as in depression and also further we're going to have research results and progress of our micro needle patch for a number of these psychedelic pharmaceuticals for actually the micro dosing program that we have for SO5 and DMT and DNA even LSD and combinations thereof and what's also significant which is part of the company though we're actually selling our SO5 and part of our program which we actually found that's what the companies which we founded on to revive therapeutics and we'll can discuss that later on if you'd like that will provide non-dilutive funding for the company to advance its clinical development with ketamine and its micro dosing strategy all under the umbrella of our micro needle delivery technology so it's really exciting for us over the next over the next six months. Yeah this is great and it's funny because I found your about your company through one of our members one of our members like you got to put this company on your watch list I had never heard of your company before a lot of our members are hearing about it now for the first time and a lot of our members when I started talking about the fact that we were going to interview this morning started to buy started to buy oh they just started to buy it so they started getting at 40 cents 41 cents 42 cents they're already up and it's exciting to hear from you directly so that they get a better idea of where the company's going so in knowing that the psychedelic space is growing every day very quickly we've seen mind medicine 10x and I was one of the first ones ever to interview mind medicine when they were 30 cents and they went through this little dull period for like about six months where they didn't do anything and then out of nowhere it went from 30 cents to four bucks that's the stock market I try to explain this to people I was like you know whenever stocks don't go up there's this thing and I always I joke about it but it's really real it's like when stocks are going down people are panicking but that's really the best time to buy and when stocks are up people are beating their chest talking about how great they are that's the best time to sell it's so hard to teach people to think that way because everybody does the opposite right people are in like people and it's this is why I have a trading club people chase green what I do is I teach them to chase the red because that's how you buy something on sale it's the same thing that Warren Buffett does like when when Warren Buffett buys a stock he doesn't chase it at all-time highs he buys them when they're really beating down a lot of people forget when Goldman Sachs during the last major correction in 2008 was in major trouble Warren Buffett wrote a huge check for $500 million when they were dirt cheap he's made billions of dollars on that one investment that's how investors make money you buy low you wait allow the company to grow mature build revenue and when the companies had a major catalyst and they explode that's when we tell our members take profits this is a great trading strategy but for some reason so many people do it backwards now the psychedelic space like we said has been growing every day new companies are starting to emerge can you tell us what sets farm with their ink apart from the rest there's so many mind medicines out there everyone wants a piece of this sector what makes you guys unique yeah absolutely like I mean there are a number of psychedelic companies are focused on either producing their own drugs such as psilocybin in their whether it be a say a biophinsetic way or the other proprietary processes so they can be able to conduct their own research with their own supply if you will and also supply the market whether it's the clinical research or even even for the market itself when they say the regulations become more right friendly or deregulated if you will so you have that kind of bucket of companies there and then you have these other bucket of companies that have the physical asset strategy where they're opening or expanding these psychedelic based clinics such as ketamine clinics and whatnot whether they're opening new ones or doing some sort of roll-up strategy then you have that kind of bucket of companies and both strategy are fantastic for the industry and they serve the gaps of the market today and I'm a fan of all those types of companies are trying to do something in this space because we all have this common goal is to you know bring psychedelic pharmaceuticals to the forefront because basic current treatments are not working but however my opinion you know and maybe it's just being a bias because I come from a biotech background is that I believe the largest market opportunity is being a pure play biotech pharma that's focused on developing psychedelic pharmaceuticals for the for FDA approval so like the largest player in the space such as MindMed such as Compass Pathway so MindMed with their LSD and even MD&A and combinations they're up Compass Pathway with their psilocybin all going directly to the FDA approval then you have J&J a monster pharmaceutical company that recently had their ketamine nasal spray for treatment of depression all that biotech pharmaceutical based strategy and including in the mix is us you know with our focus on investing in psychedelic pharmaceuticals as a prescription for FDA approvals so we have for instance our own ketamine formulation which is a combination and then an IP in finding novel uses and delivering these psychedelics in a unique way that is safe pain-free as well as convenient so that can be taken at home so specifically our focus is commercialized a novel formation of ketamine in a proprietary needle patch that would offer these safe and effective convenient and also as a compliant way to treat the mental health such as depression or PTSD neurological disorders such as Parkinson's disease and even pain such as neuropathic or even post-operative say after surgery without the need for restricted oversight though by a healthcare professional say at a hospital or clinic so again we're going back to our thesis or our mission if you will is that we're changing the way our psychedelics are being used to treat these significant unmet medical needs with the psychedelic pharmaceuticals so that's how we kind of differentiate ourselves in this whole arena of players in the space that's great now you mentioned a little bit earlier in the interview that you guys are partnering with revive therapeutics can you please go through the partnership with us and how it benefits the company yeah so as you know farm affairs discussed that we made decision to focus our resources in commercializing ketamine for Parkinson's and depression all other types of same mental health disorders we really literally have I call it a pipeline in a patch if you will so that ketamine a micro needle patch can be used for a number of these indications and which of course are all you know multi-billion dollar market opportunities and they have significant unmet medical needs treatments right now do not work so since our inception though we were focused on developing unique or novel uses of psilocybin for specifically in neurological sources such as stroke and traumatic brain injury as well as even file patents on psilocybin to be used for certain cancer indications as an adjunct to current cancer treatments and in addition we also have an IP that combination of psilocybin with other FDA approved drugs that could potentially be used for neurological diseases now seeing that revive is building a like a one-of-a-kind psilocybin program and so and more specifically in with the not only for psychedelics but psilocybin itself with their development of an oral fin or like that listerine type fin film product and psilocybin and they're developing with the University of Wisconsin as well as they're developing their own biosynthetic version of psilocybin in partnership with North Carolina State University and they're also doing a clinical study for psilocybin in them in the for the treatment of methamphetamine methamphetamine use disorders and that's being done at the University of Wisconsin so they have this kind of like really a broad or specialized I should say psilocybin program and the decision if you say to park our psilocybin development with revive and leverage their infrastructure is a no brainer win-win outcome for both for both companies so it made sense to kind of you know really leverage that asset take it to the next level in a in a in a home if you will that has a focus where we can focus on our core which is delivering ketamine for all these other developed indications now it's vital when you're looking into a company that the company has a strong management team can you tell us a little bit about the Pharma Thayer team and what each member and the key members bring to the table yeah absolutely and you're right because it's the ability to execute at the end of the day right and now one of the things that we've done fairly well I would I would say is that we over the last six months built up a pipeline not only clinical developments of our of with ketamine and other psychedelics but also the licenses that we have for the IP for delivering them the uses of them as well as formulations right and that takes manage a deal with experience so even for myself I've had 20 years experience in the biotech field specifically with clinical stage companies that are focused on novel drug delivering drug repurposing of drugs for FDA approval and I spent my career in senior business development so such as executing license agreements partnerships to strategic alliances and whatnot and I was the founder of several biotech companies now our R&D director Dr. Owen Van Canabra he brings a wealth of R&D experience for drugs with pharmaceutical companies experience as a research scientist with Eli Lowry Canada our scientific advisory board is very strong and actually continues to grow too with Dr. Robert Hauser from South Florida University as well as Dr. Alberto Espi from University of Cincinnati both are leaders in the field of Parkinson's disease and have significant experience in the clinical studies and drug approvals for Parkinson's we also have Dr. Dr. Joga who is a former FDA director and that participating in the drug approval process within the the institution Dr. Bev Inklingen who's a director of our pharma there he's a chief scientific officer for a company called Iron Shore Pharma which was recently been granted at the approval for a drug for ADHD so our board is also consists of drug development capital market expertise and business development and we're continuing as our company is growing as you can see with the recent news development to what now we are adding core competencies in drug and clinical development areas as well as now we're in the process of building our advisory team for our depression program which is very unique. Wow you guys are really building a strong team and for our community one of the key ingredients to finding a successful company is share structure it is vital for us we love tight float stocks it's one of the reasons we wanted to have you on our show you guys have a very tight float can you talk a little bit about your share structure and how much is held by insiders and institutions yeah absolutely I mean we have a good structure our insiders own nearly 25 percent of outstanding shares on institution I would say probably another 25 to even 40 percent and then we have I mean we have approximately 55 million shares outstanding 80 million fully diluted our market cap is roughly I think like 30 million which pales in comparison to other psychedelic pubcos if you will with valuations of 250 million even up to two billion Canadian market cap so but really in reality not many investors know about us you know we really put our head down and focus on expanding our product pipeline building out our intellectual property portfolio which is consistent with 19 passes of band applications that all compasses our micro-needle delivery technology and then you know we have licenses from from technologies originated from UCLA Queens University Belfast also Academy for Parkinson's from the University of Arizona also our combination formulation from the NHRI so you know with this validated IP if you will in our in our in a clear path for drug development you know we're very unique to the field and you know we're young in the sense of because we kept our head down not really been exposed in fact this is my first live interview since our inception so you know I felt like this is a great time for us we've had some milestones so it's a good time for investors to you know learn about our story because you know we are in the couple of our value being recognized and I'm just totally happy to share our story with you and your audience well our audience is worldwide so you are going to get people calling you I promise you that okay and we'll have some new potential investors and you will have some new potential business partners from this video because we have about 100 countries that will tune into this video oh awesome an investor wanted to get in contact with you or a shareholder joint venture partner anyone what's the best way for them to reach you Fabio yeah sure like I just you know I just want to build up on something that we're going on like I mean with our low I guess you could say ultra low valuation compared to our peers you know we are changing the way how psychedelic pharmaceuticals are being used through our myconeal delivery patch and our unique ketamine formulation that will hopefully revolutionize if you will how mental health neurological and pain disorders are treated you know we have a robust FDA clinical product pipeline soon we're going to have two FDA programs going to phase two clinical studies we have a broad patent portfolio which I mentioned making us one of the few companies to have a collection of these I guess you could say psychedelic assets to lead these you know the psychedelic renaissance that we seem to be in and again with our prolific team and our value proposition is only now starting to get some recognition with your audience worldwide and with our focus of getting our word out there since the psychedelic investment community I see tremendous upside potential for pharma there and its shareholders so I encourage anyone who's listening or down the road whatnot is to visit our website at pharma there.com I'm sure you'll have that on your page as well and on but you can also email me call me or you know email info at pharma there.com our investor's desk deck is available on our website which lists out all the IP that we have you can really do a deep dive on our company it's not you can understand what we're about what we're trying to do and how we back that up not only from a patent situation but from a clinical you can really dig dive deep on the scientific rationale and even research that's was done with our program so you know we look forward to updating our shareholders and our developments over and milestones over the next several months so you know I thank you for your time and you're interested in learning about pharma there and hope to see you know you just join the join with us on this journey that we're trying to achieve to you know have our common goal of just bringing psychedelics on the forefront for mental health and neurological pain disorders. Oh this is great we specialize here at Rich DV Live of finding companies that are undervalued, under-appreciated, underexposed and we bring them to the world by doing what we're doing right now you know getting a chance to speak directly to the person who created the company speaking to the founder getting a chance to see your passion about the industry getting a chance to understand the share structure getting a chance to understand the management team getting a chance to understand how to contact you this is how we've built and worked with every client that we've worked with and we've seen a lot of those clients go up a thousand percent and I don't see any reason why you also cannot be a huge success story in the next six to 12 months now one thing I want to make sure everyone understands about Rich DV Live is that we are not licensed advisors so always do your own due diligence always do your own research before you invest in anything that we talk about here at Rich DV Live go and speak to a financial advisor chances are when you speak to a financial advisor they're gonna say oh where'd you find this pic I like it I hear it every day guys because we literally have financial advisors joining our club because they want access to great companies like your company first and that's really what we specialize in we're not the people that panic when stocks are down in fact we're the ones that are the buyers when great companies are down and then when stocks are up like I said we're not beating our chest talking the world about how great we are we're selling and that's how we trade and and that's how I teach our investors to trade and in doing that we're able to build a lot of value for ourselves create a lot of wealth as a community and then when I bring the next undervalued pic to the community the community is in a cash position so they're typically ready to to buy I don't have to tell them what to buy everybody decides based on the value of the company what they want to buy and what they want to sell and when they buy and when they sell so I just want to make sure everybody knows that guys remember if you like this video please smash the like button comment down below share the video everywhere and subscribe fabio thank you so much for joining us we wish you all the best of luck in your future endeavors our entire community be watching you very closely and if you ever have any other big breaking news I'd love to invite you back on our show so we can talk about a live absolutely and I love to share our company as we evolve and I'm always available for any type of interview that you are so I appreciate your time and you learning about our company and your audience learning about our company myself and what we're trying to achieve hopefully resonates well again if you have any questions feel free to just reach out and and just just join us on this journey so thank you very much for everyone's time and have a great day thank you fabio for joining us everybody ph rm in canada it's already up ph rrf in america also up today if you're not winning you're not watching bring the winners and we bring them to you first thank you fabio keep up the great work have a great day thank you you guys for watching